Neurotech Pharmaceuticals

Executive Summary

Neurotech Pharmaceuticals is a private, clinical-stage biotechnology company that has achieved a significant milestone with the FDA approval of ENCELTO™ (revakinagene taroretcel-lwey), the first treatment for Macular Telangiectasia Type 2 (MacTel). The company's core Encapsulated Cell Therapy (ECT) platform enables sustained delivery of therapeutic proteins directly to the eye, addressing unmet needs in chronic retinal diseases. With ENCELTO now on the market, Neurotech is positioned to capture a niche patient population while advancing its pipeline to expand ECT into larger indications such as age-related macular degeneration (AMD) and diabetic retinopathy. The platform's versatility offers potential for long-term value creation, though commercial execution and pipeline progress remain key to realizing full potential. Private ownership provides flexibility but limits visibility for public investors.

Upcoming Catalysts (preview)

• Q2 2026ENCELTO commercial launch update and early sales data85% success
• Q4 2026Initiation of Phase 2/3 trial for ECT in geographic atrophy (GA) secondary to AMD60% success
• Q1 2027Partnership or licensing deal for ECT platform in diabetic retinopathy40% success